NICE Rejects Akcea’s High-Cost Waylivra
Data Doubts Also An Issue
Executive Summary
Initial knock-back from NICE means Akcea will need to improve commercial offer.
You may also be interested in...
NICE Says Yes To Akcea’s Tegsedi After ‘Improved’ Commercial Offer
NICE has given the green light to Akcea Therapeutics’ ultra-rare disease treatment Tegsedi (inotersen) after the company offered a better “commercial arrangement.”
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.